Reportable Segment — Total Assets

Business Segments · Total Assets

Eli Lilly Reportable Segment — Total Assets increased by 13.9% to $114.94B in Q3 2025 compared to the prior quarter.

Analysis

StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ4 2023
Last reportedQ3 2025
Rolls up toTotal Assets

How to read this metric

Growth in assets relative to revenue may indicate capital-intensive expansion or potential inefficiencies in asset utilization.

Detailed definition

Represents the total value of all assets, including property, plant, equipment, inventory, and intangibles, that are dir...

Peer comparison

Standard metric for assessing segment-level capital deployment across the pharmaceutical sector.

Metric ID: lly_segment_reportable_segment_total_assets

Historical Data

5 periods
 Q4 '23Q4 '24Q1 '25Q2 '25Q3 '25
Value$64.01B$78.71B$89.39B$100.92B$114.94B
QoQ Change+23.0%+13.6%+12.9%+13.9%
YoY Change+23.0%
Range$64.01B$114.94B
CAGR+79.6%
Avg YoY Growth+23.0%
Median YoY Growth+23.0%
Current Streak4+ quarters growth

Frequently Asked Questions

What is Eli Lilly's reportable segment — total assets?
Eli Lilly (LLY) reported reportable segment — total assets of $114.94B in Q3 2025.
What does reportable segment — total assets mean?
The total value of all assets owned and used by this specific business segment.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.